COVID-19 Collection

Journal article

Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study

Abstract:: Introduzione: la pandemia da SARS-CoV-2 ha sconvolto la quotidianità in tutto il mondo. Per arginare il numero dei contagi il mondo scientifico ha sviluppato dei vaccini in tempi record sfruttando nuove tecnologie, come quella dei vaccini a mRNA. Da dicembre 2020 ad oggi sono state somministrate milioni di dosi vaccinali, con lo scopo di ottenere una copertura vaccinale il più ampia possibile. Non tutta la popolazione vaccinata sviluppa però una risposta immunitaria solida: infatti, determina...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Shields, A. M., Faustini, S. E., Hill, H. J., Al-Taei, S., Tanner, C., Ashford, F., Workman, S., Moreira, F., Verma, N., Wagg, H., Heritage, G., Campton, N., Stamataki, Z., Drayson, M. T., Klenerman, P., Thaventhiran, J. E. D., Elkhalifa, S., Goddard, S., Johnston, S., … Savic, S. (2022). Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study. Frontiers in Immunology, 13, 912571–912571.

MLA Style

Shields, AM, et al. “Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.” Frontiers in Immunology, vol. 13, 2022, pp. 912571–71.

Chicago Style

Shields, AM, SE Faustini, HJ Hill, et al. 2022. “Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.” Frontiers in Immunology 13: 912571–71.
Print

Access Document

Files:: Shields_et_al_2022_Increased_Seroprevalence_and.pdf

(Preview, Version of record, pdf, 1.3MB, Terms of use)

Publisher copy:: 10.3389/fimmu.2022.912571

Publication website:: https://thesis.unipd.it/bitstream/20.500.12608/30577/1/Zanella_Silvia3%20PDFA.pdf

Authors

+ Shields, AM More by this author

Role:: Author
ORCID:: 0000-0001-5345-2156

+ Faustini, SE More by this author

Role:: Author
ORCID:: 0000-0002-9300-5569

+ Hill, HJ More by this author

Role:: Author
ORCID:: 0000-0002-5620-0795

+ Al-Taei, S More by this author

Role:: Author

+ Tanner, C More by this author

Role:: Author
ORCID:: 0000-0002-7032-9480

More authors...

+ UK Research and Innovation More from this funder

Funder identifier:: 10.13039/100014013

Publisher:: Frontiers Media
Journal:: Frontiers in Immunology More from this journal
Volume:: 13
Pages:: 912571-912571
Article number:: 912571
Publication date:: 2022-06-02
DOI:: 10.3389/fimmu.2022.912571
EISSN:: 1664-3224
ISSN:: 1664-3224

Language:: Italian
Keywords:: Virology

Medicine

ELISPOT

Serology

T cell

Immune system

Immunization

Vaccination

Seroconversion

Vaccination schedule

Antibody

Immunology

Seroprevalence

Immunogenicity
Pubs id:: 1265402
Local pid:: pubs:1265402
Source identifiers:: W4285742145
Deposit date:: 2026-04-27
ARK identifier:: ark:/29072/ora_de71b37dd68f4634be23d0207a456fef

Terms of use

Copyright date:: 2022

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP